Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PharmaCyte Biotech, Inc. - Common Stock (NQ:PMCB)

0.5760 -0.0240 (-4.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PharmaCyte Biotech, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
PMCB Stock: 14 Things to Know About PharmaCyte Biotech as Shares Skyrocket ↗
PharmaCyte Biotech (PMCB) stock is taking off Wednesday and there are a few things that potential investors need to know about the company. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers PharmaCyte Biotech (NASDAQ:PMCB) shares rose 71.92% to $5.88 during Wednesday's pre-market session. The market value of their outstanding shares is at $9.4... 
Via Benzinga
News headline image
PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers ADMA Biologics (NASDAQ:ADMA) stock rose 18.79% to $1.77 during Monday's pre-market session. The company's market cap stands at $226.8 million. The company... 
Via Benzinga
News headline image
66 Biggest Movers From Yesterday ↗
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers Cellect Biotechnology (NASDAQ:APOP 
Via Benzinga
News headline image
78 Biggest Movers From Friday ↗
Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering. Flora Growth... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Biolase (NASDAQ:BIOL) stock increased by 38.01% to $0.87 during Friday's regular session. Trading volume for this security as of 12:35 EST is 80.8 million,... 
Via Benzinga
News headline image
53 Stocks Moving In Friday's Mid-Day Session ↗
Gainers BIOLASE, Inc. (NASDAQ: BIOL) shares climbed 30.9% to $0.8270 after the company reported better-than-expected Q2 sales. The company said it continues to experience demand... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Edge Higher; Disney Reports Upbeat Q3 Earnings ↗
Following the market opening Friday, the Dow traded up 0.04% to 35,512.89 while the NASDAQ rose 0.20% to 14,845.17. The S&P also rose, gaining 0.11% to 4,465.85. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
77 Biggest Movers From Yesterday ↗
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares surged 65.4% to close at $2.10 on Thursday after the company announced it is expanding its blockchain business to... 
Via Benzinga
News headline image
PharmaCyte Biotech Announces Closing of $15-Million Public Offering
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Update on Study Progress and Uplist to Nasdaq
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Reverse Stock Split
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Results of Vote at Annual Meeting of Stockholders
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Shareholders Vote to Increase the Authorized Capital
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Adjournment of Annual Meeting of Stockholders, Recording of Stockholder Meeting Available
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Details to Attend This Week’s Virtual Annual Meeting of Shareholders
From PharmaCyte Biotech, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.